Skip to main content
Caplight Logo









Outpace Bio

Outpace Bio

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://www.outpacebio.com/

Last Round

Series B

Aug 1, 2024

Total Funding Raised

$174M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Outpace Bio is a biotechnology company that develops AI-powered protein design technologies to engineer immune cells for more effective and safer cell therapies targeting solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Application

Keywords

computational protein designcell therapysolid tumorsCAR-T therapyAI protein designsynthetic biologyprotein engineeringnext generation cell therapiesprogrammable medicinedrug discovery platformimmunotherapyde novo protein designbiotech partnershipstumor microenvironmentoncology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Outpace Bio Comparables

Compare Outpace Bio with similar companies based on industry and business-model similarity.

Outpace Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ArsenalBio
78%
LabGenius Therapeutics
74%
Evozyne
73%

Outpace Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BAug 1, 2024
Series AMar 31, 2021

Key People

Founding team and executive leadership

Scott Boyken

Co-Founder, Chief Technology Officer

Founding Team

Marc Lajoie

Co-founder, Chief Executive Officer

Founding Team

Outpace Bio Investors

Notable investors and investment history

Outpace Bio investors
InvestorRounds
Surveyor CapitalSeries B
RA Capital ManagementSeries B
WRF CapitalSeries A, Series B
Playground GlobalSeries A, Series B
ARTIS VenturesSeries B, Series A
Washington Research Foundation CapitalSeries A, Series B
Abstract VenturesSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 40% MoM.

  • Nov 4, 2025

    Lead candidate OPB-101 targeting ovarian cancer to begin dosing in 2025.

Outpace Bio Filings

Explore SEC and related filing metadata, where available.

Outpace Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Outpace Bio's valuation, stock price, and market status.

Is Outpace Bio a public or private company?

Outpace Bio is a private company.

What is the current stock price of Outpace Bio?

Outpace Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Outpace Bio worth (valuation)?

Valuation information for Outpace Bio is not publicly available.

Can I buy Outpace Bio stock?

Outpace Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Outpace Bio's last funding round?

Outpace Bio's most recent funding round was Series B on August 1, 2024.

Who are the main investors in Outpace Bio?

Key investors in Outpace Bio include RA Capital Management, ARTIS Ventures.

Will Outpace Bio IPO soon?

No public IPO plans have been announced for Outpace Bio.

How can I track Outpace Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Outpace Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range63
Year Founded2020
Last FundingAug 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?